Few Peanut Allergy Patients Tolerate Peanuts after Immunotherapy

by Ramya Rachamanti on  September 13, 2019 at 6:01 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Desensitization to peanuts is maintained only in few patients after discontinuing or reducing OIT, according to a study published in The Lancet. And, blood tests done before OIT could predict the success of therapy.
Few Peanut Allergy Patients Tolerate Peanuts after Immunotherapy
Few Peanut Allergy Patients Tolerate Peanuts after Immunotherapy

Peanut allergy is one of the most common food allergies in the United States. Though previous studies have shown that OIT can desensitize patients and prevent life-threatening allergic reactions, the optimal duration and dose is unknown.

Show Full Article


Investigators at Stanford University enrolled 120 people aged 7 to 55 with diagnosed peanut allergy in the Peanut Oral Immunotherapy Study: Safety Efficacy and Discovery, or POISED.

While otherwise avoiding peanut throughout the trial, 95 participants received gradually increasing daily doses of peanut protein up to 4 grams, and 25 participants received daily placebo oat flour OIT.

After 24 months, participants were given gradually increasing amounts of peanut in a controlled environment, to assess their tolerance. Of those participants who received peanut OIT, 83% passed the peanut challenge without an allergic reaction, while only 4% on placebo OIT did so.

Those on OIT who passed the challenge were then randomized to receive either placebo OIT or were switched to a 300-mg daily dose of peanut protein.

One year later, more participants on 300-mg peanut OIT (37%) passed the challenge than those on placebo OIT (13%), confirming insights from smaller trials that desensitization is maintained in only a minority of participants after OIT is discontinued or reduced.

Participants who passed food challenges also had lower initial levels of allergic antibodies to peanut protein and other indicators of allergic activity in the blood. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and will allow for regular food consumption without allergic symptoms.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive